ABY 029

Drug Profile

ABY 029

Alternative Names: ABY-029 trifluoroacetate salt; fluorescently-labeled Anti-EGFR affibody molecule; IRDye 800CW maleimide-labeled affibody peptide

Latest Information Update: 24 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affibody; Dartmouth College; LI-COR Biosciences
  • Developer Dartmouth College
  • Class Imaging agents; Peptide diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Epidermal growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Glioma

Most Recent Events

  • 20 Sep 2017 Dartmouth-Hitchcock Medical Center plans a phase I trial for Head and neck cancer in USA (NCT03282461)
  • 23 May 2017 Dartmouth College plans a phase 0 trial for Soft-tissue Sarcoma (Diagnosis) in USA (NCT03154411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top